Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)

被引：0
|
作者：
Samalin, E. [1 ]
Bouche, O. [2 ]
Thezenas, S. [1 ]
Francois, E. [3 ]
Adenis, A. [4 ]
Bennouna, J. [5 ]
Taieb, J. [6 ]
Desseigne, F. [7 ]
Laurent-Puig, P. [6 ]
Ychou, M. [8 ]
机构：
[1] CRLC Val dAurelle, Stat, Montpellier 5, France
[2] CHU Robert Debre, Reims, France
[3] Ctr Antoine Lacassagne, F-06054 Nice, France
[4] Ctr Oscar Lambret, F-59020 Lille, France
[5] Ctr Rene Gauducheau, F-44035 Nantes, France
[6] Hop Georges Pompidou, APHP, Paris 15, France
[7] Ctr Leon Berard, F-69373 Lyon, France
[8] CRLC Val dAurelle, Oncol, Montpellier 5, France
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71736-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S418 / S418
页数：1
相关论文
共 50 条
  • [21] DISTRIBUTION OF KRAS STATUS ACROSS TREATMENT PATTERNS IN 1ST AND 2ND LINE METASTATIC COLORECTAL CANCER (MCRC) PATIENTS IN WESTERN EUROPE
    Rose, Mathieu
    Iqbal, Sheikh
    Naoshy, Sarah
    Mehta, Jyotsna
    Chau, Ian
    ANNALS OF ONCOLOGY, 2012, 23 : 79 - 80
  • [22] CETUFTIRI, a new combination of UFT with leucovorin (LV), irinotecan, and cetuximab as first-line treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Preliminary results from a multicenter phase II trial
    Bennouna, J.
    Faroux, R.
    Francois, E.
    Ligeza, C.
    El Hannani, C.
    Perrier, H.
    Jacob, J.
    Desseigne, F.
    Perrocheau, G.
    Douillard, J. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Final results of a randomized phase III trial comparing irinotecan plus oxaliplatin (IROX) to irinotecan monotherapy in patients with metastatic colorectal cancer (MCRC) previously treated with fluoropyrimidines
    Haller, Daniel G.
    Rothenberg, Mace L.
    Wong, Alfred O.
    Koralewski, Piotr M.
    Miller, Wilson H., Jr.
    Bodoky, Gyorgy
    Olivatto, Luis O.
    Burger, Brent G.
    Kearney, Jill G.
    Garay, Carlos A.
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 70
  • [24] A phase II trial of a biweekly schedule of capecitabine (X) plus irinotecan (1) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Perez-Manga, G
    Gonzalez, MC
    Lopez, P
    Gonzalez, E
    Belon, J
    Molina, M
    Pachon, V
    Iglesias, L
    Siso, I
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 256S - 256S
  • [25] Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study
    Li, Baoqi
    Yang, Wenwei
    Liu, Na
    Bi, Deying
    Yang, Tingting
    Wu, Guifu
    Sun, Yongkun
    BRITISH JOURNAL OF CANCER, 2024, 131 (11) : 1775 - 1780
  • [26] Combination Chemotherapy With Capecitabine (C), Irinotecan (I) Oxaliplatin (O) and Bevacizumab (B) (XELOXIRIA) as First Line Treatment of Metastatic Colorectal Cancer (MCRC) - Preliminary Results of a Phase I-II Trial
    Bazarbashi, S.
    Aljubran, A.
    Soudy, H.
    Alzahrani, A.
    Darwish, A.
    Eltaigani, A.
    Nabil-Ahmed, M.
    Edesa, W.
    Shoukri, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S425 - S425
  • [27] Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients: A phase II multicentric study
    Lapeyre-Prost, A.
    Pernot, S.
    Sigrand, J.
    Mary, F.
    Le Malicot, K.
    Aparicio, T.
    Dahan, L.
    Caroli-Bosc, F-X.
    Lecomte, T.
    Doat, S. Racine
    Marthey, L.
    Desrame, J.
    Lepage, C.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 160 - 160
  • [28] Bevacizumab (bev) combined with chemotherapy as 2nd-line treatment for metastatic colorectal cancer (mCRC): results from the phase II BEVACOLOR study
    Bennouna, J.
    Husseini, F.
    Delord, J. P.
    Borg, C.
    Trillet-Lenoir, V.
    Faroux, R.
    Francois, E.
    Ychou, M.
    Chaaban, B.
    Douillard, J. Y.
    EJC SUPPLEMENTS, 2009, 7 (02): : 344 - 344
  • [29] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216)
    Stein, Alexander
    Binder, Mascha
    Goekkurt, Eray
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas Jens
    Doerfel, Steffen
    Al-Batran, Salah-Eddin
    Karthaus, Meinolf
    Pelzer, Uwe
    Simnica, Donjete
    Waberer, Lisa
    Hinke, Axel
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [30] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) - Final Results of the phase II AVETUX trial (AIO-KRK-0216)
    Binder, Mascha
    Goekkurt, Eray
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas
    Doerfel, Steffen
    Al-Batran, Salah
    Karthaus, Meinolf
    Pelzer, Uwe
    Simnica, Donjete
    Waberer, Lisa
    Hinke, Axel
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    Tintelnot, Joseph
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
12345